In a move set to redefine the pharmaceutical industry, Recipharm has unveiled ReciPredict, a breakthrough platform designed to optimize drug product development and manufacturing processes. This innovative tool aims to reduce active pharmaceutical ingredient (API) consumption by 30-70% during development and scale-up, and accelerate the journey to the clinical stage by up to six months, significantly cutting down the time it takes for new drugs to reach patients.
A New Era in Drug Development
ReciPredict is poised to revolutionize the pharmaceutical landscape by incorporating advanced Quality by Design (QbD) principles. Leveraging material sciences, statistical tools, and sophisticated modeling and simulation, the platform provides a fully integrated approach to drug development. This integration is designed to streamline each phase of the development cycle, from initial formulation to manufacturing, ensuring efficiency and reliability at every stage.
Dr. Uwe Hanenberg, PhD, Head of Product Implementation at Recipharm, highlights the advantages of the platform:
“ReciPredict accelerates the journey of new drugs to the clinical stage by 3-6 months, substantially expediting the drug development process. It also offers significant cost savings by reducing API consumption by 30% to 70%. Another crucial advantage is that applying ReciPredict de-risks tech transfers by identifying the right parameters for best process robustness, consequently achieving consistent and high-quality results.”
How ReciPredict Works
The platform marries the expertise of data science and statistics with advanced modeling capabilities. By connecting critical process parameters, material attributes, and drug product quality attributes, ReciPredict enables precise predictions of how different materials and processes will impact the final product. This level of control is a significant leap forward for pharmaceutical companies that rely on Quality by Design principles to ensure product consistency and compliance.
Key Features of ReciPredict
ReciPredict’s standout features include:
- Data Science and Statistical Expertise: The platform’s team of experts uses data-driven insights to enhance development outcomes.
- Advanced Modelling Tools: These tools allow for accurate simulations of various manufacturing processes.
- Powder Characterization: Advanced techniques such as FT4, Accupyc, and BET, along with the Style One Evo compression and compaction simulator, ensure detailed analysis of material properties.
- Comprehensive Statistical Analysis: Statistical models and tools ensure robust predictions and optimizations across processes.
A Versatile Tool for Every Stage
ReciPredict can be applied across numerous phases of drug development, including trial design, data analysis, in silico formulations, tech transfers, and process optimization. Its versatility ensures that it can be utilized across all products, technologies, and manufacturing sites, making it a game-changer for companies looking to streamline and enhance their drug development pipeline.
Recipharm’s launch of ReciPredict marks a significant step toward modernizing the pharmaceutical industry, offering time and cost-saving benefits while ensuring product quality and consistency. For companies looking to stay competitive in the fast-evolving pharmaceutical landscape, ReciPredict could be the solution that bridges the gap between development speed and quality.